Division of Aging Biology Funding Opportunity Announcements
DAB is currently seeking applications in response to funding opportunity announcements in the biology of aging and in geroscience. Please see below for active FAO developed by DAB or joined by DAB. DAB also seeks applications related to Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) in some specific areas.
The full list of NIA-wide active funding opportunities and NIA-wide AD/ADRD funding opportunities can be found online. Read NIA's research and funding frequently asked questions.
The table below contains funding opportunity announcements that are currently being funded in full or in part by the Division of Aging Biology (DAB). The FOAs are grouped by RFA, PAR, then PA, and listed in ascending order of the expiration date.
| FOA Number | Title | Released | Expires | DAB Contact |
|---|---|---|---|---|
| RFA-AG-20-044 | The Biological Mechanisms of Metformin Effects on Aging and Longevity (R01 Clinical Trial Not Allowed) | 7-Aug-19 | 22-Jan-20 | Max Guo, Ph.D/Yih-Woei Fridell, Ph.D |
| RFA-AG-20-036 | Biology of Aging in Reproductive Tissues (R01 Clinical Trial Not Allowed) | 5-Jun-19 | 30-Jan-20 | Candace L. Kerr, Ph.D |
| RFA-AG-20-039 | Lipid Signaling in Healthspan and Longevity Regulation (R01 Clinical Trial Not Allowed) | 24-Jun-19 | 4-Feb-20 | Yih-Woei Fridell, Ph.D |
| RFA-AG-20-035 | Building Resources for the Basic Biology of Aging in Health Disparities Research (R24 Clinical Trial Not Allowed) | 31-Jul-19 | 20-Oct-20 | Ronald A. Kohanski, Ph.D |
| PAR-19-249 | Environmental Influences on Aging-Effects of Extreme Weather and Disaster Events on Aging Processes (R01 Clinical Trial Not Allowed) | 12-Apr-19 | 9-Mar-21 | Ronald A. Kohanski, Ph.D |
| PAR-19-304 | Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional) | 25-Jun-19 | 17-Jul-22 | Rebecca A. Fuldner, Ph.D |
| PAR-19-305 | Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional) | 25-Jun-19 | 17-Jul-22 | Rebecca A. Fuldner, Ph.D |
| Comparative Biology of Neurodegeneration (R21) | 27-Oct-16 | 08-Jan-20 | Francesca Macchiarini, Ph.D | |
| Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R41/R42 Clinical Trial Not Allowed) | 20-Dec-17 | 06-Jan-21 | Max Guo, Ph.D | |
| Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R43/R44 Clinical Trial Not Allowed) | 20-Dec-17 | 06-Jan-21 | Max Guo, Ph.D | |
| Changes in Cellular Architecture During Aging (R01) | 22-Sep-16 | 08-Jan-20 | Jose Velazquez, Ph.D | |
| Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional) | 11-Jan-18 | 08-May-21 | Candace L. Kerr, Ph.D | |
| Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional) | 11-Jan-18 | 08-May-21 | Candace L. Kerr, Ph.D | |
| Underactive Bladder and Detrusor Activity in Aging (R01 Clinical Trial Optional) | 11-Jan-18 | 08-May-21 | Candace L. Kerr, Ph.D | |
| Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional). | 3-Apr-18 | 8-May-21 | Francesca Macchiarini, Ph.D | |
| Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional). | 3-Apr-18 | 8-May-21 | Francesca Macchiarini, Ph.D |